Pharmaceutical companies are increasingly adopting decentralized trial models, reducing average Phase III trial completion timelines by an estimated four months.
Remote Data Collection
Wearable medical devices and integrated home testing kits allow continuous physiological monitoring. This approach lowers patient drop-out rates from 30 percent to under 12 percent across major oncology studies.
Regulatory Compliance Standards
Health authorities have issued updated guidance on remote electronic source data verification, clarifying audit trail expectations for decentralized clinical trial platforms.